Clinical Study
25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy
Table 1
Characteristics and pre-25-gauge microincision vitrectomy course of 15 glaucomatous eyes.
| Patient no./sex/
age, yrs | Eye | Type of
glaucoma | Pre-25GMIVS
retinal disease | Period of 25GMIVS after TLE (M) | Site of
bleb | Pre-TLE
vitrectomy | Pre-25GMIVS
IVB | Pre-25GMIVS
pseudophakia |
| | 1/M/45 | L | Trauma | RRD | 4 | Upper temporal | N | N | Y | | 2/M/58 | L | NVG | BRVO/VH | 30 | Upper nasal | N | N | N | | 3/M/62 | R | NVG | PDR/VH | 48 | Upper temporal | N | Y | Y | | 4/F/60 | L | NVG | PDR/TRD | 36 | Upper nasal | N | Y | N | | 5/M/68 | L | NVG | PDR/VH | 10 | Upper nasal | Y | Y | Y | | 6/F/62 | L | Uveitis | MH | 55 | Upper nasal | N | N | Y | | 7/F/44 | R | NVG | PDR/VH/CD | 0.5 | Upper | N | Y | Y | | 8/F/83 | R | Malignant glaucoma | Malignant glaucoma | 1 | Upper nasal | N | N | Y | | 9/F/33 | L | Developmental
glaucoma | Lens luxation | 105 | Upper nasal | N | N | N | | 10/M/52 | R | POAG | Endophthalmitis | 0.3 | Upper temporal | N | N | N | | 11/M/59 | R | POAG | ERM | 50 | Upper temporal and nasal | N | N | N | | 12/M/61 | R | NVG | PDR/VH | 25 | Upper temporal | Y | N | Y | | 13/F/56 | R | NVG | PDR | 7 | Upper temporal | Y | N | Y | | 14/F/77 | L | Malignant glaucoma | Choroidal hemorrhage | 1 | Upper temporal | N | N | Y | | 15/M/41 | R | NVG | PDR/VH | 6 | Upper nasal | N | N | N |
| | Mean 57.4 | | NVG 53% | PDR 47% | 25.3 | | 20% | 27% | 60% |
|
|
25GMIVS: 25-gauge microincision vitrectomy surgery; TLE: trabeculectomy; IVB: intravitreal injections of bevacizumab; NVG: neovascular glaucoma; TRD: tractional retinal detachment; RRD: rhegmatogenous retinal detachment; BRVO: branch retinal vein occlusion; PDR: proliferative diabetic retinopathy; VH: vitreous hemorrhage; MH: macular hole; ERM: epiretinal membrane; POAG: primary open angle glaucoma; CD: choroidal detachment.
|
